The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Carmine Zoccali

Correspondence and offprint requests to: Carmine Zoccali; E-mail:

[email]@tin.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Correspondence and offprint requests to: Carmine Zoccali; E-mail:. 2012
  • Nephrology, Dialysis and Transplantation Unit, Ospedali Riuniti, Reggio Calabria, Italy. 2002 - 2011
  • CNR-IBIM c/o EUROLINE, di Ascrizzi Vincenzo, Via Vallone Petrara 55-57, 89132 Reggio Calabria, Italy. 2002 - 2011
  • Unità Operativa di Nefrologia, Dialisi e Trapianto Renale Ospedali Riuniti and IBIM-CNR, Epidemiologia Clinica e Fisiopatologia delle Malattie Renali e dell'Ipertensione Arteriosa, Reggio Calabria, Italy. 2011
  • Nephrology, Dialysis and Transplantation Unit and CNR-IBIM Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy. 2003 - 2011
  • presso Euroline, Via Vallone Petrara 57, 89124 Reggio Calabria, Italy. 2009
  • Nephrology and Renal Transplantation Unit and Consiglio Nazionale delle Ricerche, Instituto di Biomedicina, Ospedali Riuniti, Reggio Cal, Italy. 2009
  • CNR-IBIM, Institute of Biomedicine, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension & Division of Nephrology, Dialysis and Transplantation, Italy. 2008
  • Consiglio Nationale delle Ricerche (CNR)-Istituto di Biomedicina (IBIM), Division of Nephrology, Dialysis and Transplantation, Reggio Calabria, Italy. 2008
  • Istituto di Biomedicina-Epidemiologia Clinica e Fisiopatologia delle malattie Renali e dell'Ipertensione Arteriosa e Unita Operativa di Nefrologia, Dialisi e Trapianto Renale, Ospedali Riuniti, Reggio Calabria, Italy. 2003 - 2008
  • CNR-IBIM, National Research Council-Institute of Biomedicine, Reggio Calabria, Italy. 2008
  • Unità Operativa di Nefrologia Dialisi e Trapianto Renale e Ipertensione Arteriosa, Ospedali Riuniti 89124 Reggio Calabria, Italy. 2008
  • CNR-IBIM Istituto di Biomedicina - Consiglio Nazionale delle Ricerche c/o Divisione di Nefrologia e Dialisi Ospedali Riuniti - 89100 Reggio Calabria, Italy. 2007
  • Laboratorio di Epidemiologia, Clinica e Fisiopatologia delle Malattie, Renali, e dell'Ipertensione Arteriosa, Italy. 2003
  • Centre of Clinical Physiology and Division of Nephrology, Morelli Hospital, Reggio Cal, Italy. 2001 - 2002
  • Clinical Physiology Center of the National Research Council, Unit of Nephrology, Dialysis and Transplantation, RC Hospital, Italy. 2002
  • CNR, Division of Nephrology, Centre of Clinical Physiology and Renal Unit, Via Sbarre Inferiori 39, Italy. 2002
  • Unità Opertativa di Nefrologia, Dialisi e Trapianto, Reggio Calabria, Italy. 2002

References

  1. Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. Spoto, B., Testa, A., Parlongo, R.M., Tripepi, G., D'Arrigo, G., Mallamaci, F., Zoccali, C. Nephrol. Dial. Transplant. (2012) [Pubmed]
  2. Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. Spoto, B., Testa, A., Parlongo, R.M., Tripepi, G., Trischitta, V., Mallamaci, F., Zoccali, C. Nephrol. Dial. Transplant. (2012) [Pubmed]
  3. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. Zoccali, C., Ruggenenti, P., Perna, A., Leonardis, D., Tripepi, R., Tripepi, G., Mallamaci, F., Remuzzi, G. J. Am. Soc. Nephrol. (2011) [Pubmed]
  4. ACE inhibition is renoprotective among obese patients with proteinuria. Mallamaci, F., Ruggenenti, P., Perna, A., Leonardis, D., Tripepi, R., Tripepi, G., Remuzzi, G., Zoccali, C. J. Am. Soc. Nephrol. (2011) [Pubmed]
  5. Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? Zoccali, C., Mallamaci, F. J. Ren. Nutr (2011) [Pubmed]
  6. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. Zoccali, C., Postorino, M., Marino, C., Pizzini, P., Cutrupi, S., Tripepi, G. J. Intern. Med. (2011) [Pubmed]
  7. Blood pressure control: hydrogen sulfide, a new gasotransmitter, takes stage. Zoccali, C., Catalano, C., Rastelli, S. Nephrol. Dial. Transplant. (2009) [Pubmed]
  8. FGF-23 in dialysis patients: ready for prime time?. Zoccali, C. Nephrol. Dial. Transplant. (2009) [Pubmed]
  9. The databases: renal replacement therapy since 1989--the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA). Zoccali, C., Kramer, A., Jager, K. Clin. J. Am. Soc. Nephrol (2009) [Pubmed]
  10. Urotensin II: a cardiovascular and renal update. Zoccali, C., Carmine, Z., Mallamaci, F. Curr. Opin. Nephrol. Hypertens. (2008) [Pubmed]
  11. Urotensin II and cardiomyopathy in end-stage renal disease. Zoccali, C., Mallamaci, F., Benedetto, F.A., Tripepi, G., Pizzini, P., Cutrupi, S., Malatino, L. Hypertension (2008) [Pubmed]
  12. The MAURO study: multiple intervention and audit in renal diseases to optimize care. Zoccali, C., Leonardis, D., Enia, G., Postorino, M., Mallamaci, F. J. Nephrol. (2008) [Pubmed]
  13. Cardiovascular risk in patients with chronic kidney disease: not high enough to enter the major league?. Zoccali, C. Curr. Hypertens. Rep. (2008) [Pubmed]
  14. The burden of cardiovascular disease in patients with chronic kidney disease and in end-stage renal disease. Zoccali, C. Contrib. Nephrol (2008) [Pubmed]
  15. Obesity, diabetes, adiponectin and the kidney: a podocyte affair. Zoccali, C., Mallamaci, F. Nephrol. Dial. Transplant. (2008) [Pubmed]
  16. It is important to lower homocysteine in dialysis patients. Zoccali, C., Mallamaci, F., Tripepi, G. Semin. Dial (2007) [Pubmed]
  17. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Zoccali, C., Maas, R., Cutrupi, S., Pizzini, P., Finocchiaro, P., Cambareri, F., Panuccio, V., Martorano, C., Schulze, F., Enia, G., Tripepi, G., Boger, R. Nephrol. Dial. Transplant. (2007) [Pubmed]
  18. The endothelium as a target in renal diseases. Zoccali, C. J. Nephrol. (2007) [Pubmed]
  19. Prognostic value of the New York Heart Association classification in end-stage renal disease. Postorino, M., Marino, C., Tripepi, G., Zoccali, C. Nephrol. Dial. Transplant. (2007) [Pubmed]
  20. How important is echocardiography for risk stratification in follow-up of patients with chronic kidney disease?. Zoccali, C. Nature Clinical Practice. Nephrology (2007) [Pubmed]
  21. Cardiovascular risk profile assessment and medication control should come first. Zoccali, C., Mallamaci, F., Tripepi, G. Semin. Dial (2007) [Pubmed]
  22. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. Zoccali, C., Benedetto, F.A., Tripepi, G., Mallamaci, F., Rapisarda, F., Seminara, G., Bonanno, G., Malatino, L.S. J. Am. Soc. Nephrol. (2006) [Pubmed]
  23. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Zoccali, C., Kielstein, J.T. Curr. Opin. Nephrol. Hypertens. (2006) [Pubmed]
  24. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. Zoccali, C., Benedetto, F., Mallamaci, F., Tripepi, G., Cutrupi, S., Pizzini, P., Malatino, L.S., Bonanno, G., Seminara, G. J. Hypertens. (2006) [Pubmed]
  25. A green light for troponin T in the cardiovascular risk stratification of continuous ambulatory peritoneal dialysis patients? Zoccali, C., Mallamaci, F. Kidney Int. (2006) [Pubmed]
  26. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? Zoccali, C., Tripepi, G., Mallamaci, F. J. Am. Soc. Nephrol. (2006) [Pubmed]
  27. Homocysteine and risk in end-stage renal disease: a matter of context. Zoccali, C., Mallamaci, F. Kidney Int. (2006) [Pubmed]
  28. Mendelian randomization: a new approach to studying epidemiology in ESRD. Zoccali, C., Testa, A., Spoto, B., Tripepi, G., Mallamaci, F. Am. J. Kidney Dis. (2006) [Pubmed]
  29. Renal impairment: a risk factor for ischemic heart disease. Zoccali, C. Curr. Opin. Pharmacol (2006) [Pubmed]
  30. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G., Cutrupi, S., Pizzini, P., Malatino, L. Kidney Int. (2006) [Pubmed]
  31. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. Zoccali, C. J. Hypertens. (2006) [Pubmed]
  32. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. Zoccali, C. J. Am. Soc. Nephrol. (2006) [Pubmed]
  33. Inflammation as a mediator of the link between mild to moderate renal insufficiency and endothelial dysfunction in essential hypertension. Zoccali, C., Maio, R., Tripepi, G., Mallamaci, F., Perticone, F. J. Am. Soc. Nephrol. (2006) [Pubmed]
  34. Chronic kidney disease epidemics--a gap in effectiveness: the distance between potential and actual treatment benefits. Zoccali, C., Cambareri, F. J. Nephrol. (2006) [Pubmed]
  35. Low triiodothyronine and survival in end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G., Cutrupi, S., Pizzini, P. Kidney Int. (2006) [Pubmed]
  36. Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?. Zoccali, C. Kidney Int. (2006) [Pubmed]
  37. Clinical databases in nephrology: research and clinical practice goals and challenges. Zoccali, C. J. Nephrol. (2006) [Pubmed]
  38. Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases. Zoccali, C. Curr. Opin. Nephrol. Hypertens. (2005) [Pubmed]
  39. Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. Zoccali, C., Tripepi, G., Cambareri, F., Catalano, F., Finocchiaro, P., Cutrupi, S., Pizzini, P., Testa, A., Spoto, B., Panuccio, V., Enia, G., Mallamaci, F. J. Ren. Nutr (2005) [Pubmed]
  40. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. Zoccali, C., Tripepi, G., Cutrupi, S., Pizzini, P., Mallamaci, F. J. Am. Soc. Nephrol. (2005) [Pubmed]
  41. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Zoccali, C., Enia, G., Tripepi, G., Panuccio, V., Mallamaci, F. Perit. Dial. Int (2005) [Pubmed]
  42. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Zoccali, C. Curr. Opin. Nephrol. Hypertens. (2005) [Pubmed]
  43. Predictors of cardiovascular death in ESRD. Zoccali, C., Tripepi, G., Mallamaci, F. Semin. Nephrol. (2005) [Pubmed]
  44. Novel cardiovascular risk factors in end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G. J. Am. Soc. Nephrol. (2004) [Pubmed]
  45. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. Zoccali, C., Benedetto, F.A., Mallamaci, F., Tripepi, G., Giacone, G., Cataliotti, A., Seminara, G., Stancanelli, B., Malatino, L.S. J. Am. Soc. Nephrol. (2004) [Pubmed]
  46. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Zoccali, C., Benedetto, F.A., Mallamaci, F., Tripepi, G., Giacone, G., Stancanelli, B., Cataliotti, A., Malatino, L.S. Kidney Int. (2004) [Pubmed]
  47. Cardiac consequences of hypertension in hemodialysis patients. Zoccali, C., Benedetto, F.A., Tripepi, G., Mallamaci, F. Semin. Dial (2004) [Pubmed]
  48. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G. Nephrol. Dial. Transplant. (2004) [Pubmed]
  49. Leptin and biochemical markers of bone turnover in dialysis patients. Zoccali, C., Panuccio, V., Tripepi, G., Cutrupi, S., Pizzini, P., Mallamaci, F. J. Nephrol. (2004) [Pubmed]
  50. Inflammation and atherosclerosis in end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G. Blood Purif. (2003) [Pubmed]
  51. Another Marker of Cardiac Dysfunction in Dialysis Patients?. Zoccali, C. Nephron. Clin. Pract (2003) [Pubmed]
  52. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G. Kidney Int. Suppl. (2003) [Pubmed]
  53. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Zoccali, C., Mallamaci, F., Panuccio, V., Tripepi, G., Cutrupi, S., Parlongo, S., Catalano, F., Tanaka, S., Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y. Kidney Int. Suppl. (2003) [Pubmed]
  54. ADMA: a critical cardio-renal link in heart failure?. Zoccali, C. Eur. J. Clin. Invest. (2003) [Pubmed]
  55. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G. Kidney Int. Suppl. (2003) [Pubmed]
  56. Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Zoccali, C., Benedetto, F.A., Mallamaci, F., Tripepi, G., Cutrupi, S., Parlongo, S., Malatino, L.S., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Nicocia, G., Buemi, M. Eur. J. Clin. Invest. (2003) [Pubmed]
  57. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G., Benedetto, F.A., Parlongo, S., Cutrupi, S., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Cataliotti, A., Malatino, L.S. J. Hypertens. (2003) [Pubmed]
  58. Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Zoccali, C., Mallamaci, F., Tripepi, G., Parlongo, S., Cutrupi, S., Benedetto, F.A., Bonanno, G., Seminara, G., Fatuzzo, P., Rapisarda, F., Malatino, L.S. Kidney Int. (2003) [Pubmed]
  59. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. Zoccali, C., Mallamaci, F., Tripepi, G., Cutrupi, S., Parlongo, S., Malatino, L.S., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Stancanelli, B., Nicocia, G., Buemi, M. J. Intern. Med. (2003) [Pubmed]
  60. Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G., Benedetto, F.A., Parlongo, S., Cutrupi, S., Iellamo, D., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Cataliotti, A., Malatino, L.S. J. Am. Soc. Nephrol. (2003) [Pubmed]
  61. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. Zoccali, C., Benedetto, F.A., Maas, R., Mallamaci, F., Tripepi, G., Malatino, L.S., Böger, R. J. Am. Soc. Nephrol. (2002) [Pubmed]
  62. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. Zoccali, C., Mallamaci, F., Tripepi, G. J. Am. Soc. Nephrol. (2002) [Pubmed]
  63. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F.A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Cataliotti, A., Stancanelli, B., Malatino, L.S., Cateliotti, A. Circulation (2002) [Pubmed]
  64. Hypertension in end-stage renal disease: target values, methods of measurement and drug therapy. Zoccali, C. J. Nephrol. (2002) [Pubmed]
  65. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Zoccali, C., Mallamaci, F., Maas, R., Benedetto, F.A., Tripepi, G., Malatino, L.S., Cataliotti, A., Bellanuova, I., Böger, R. Kidney Int. (2002) [Pubmed]
  66. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Zoccali, C., Mallamaci, F., Tripepi, G., Parlongo, S., Cutrupi, S., Benedetto, F.A., Cataliotti, A., Malatino, L.S. Hypertension (2002) [Pubmed]
  67. Hypertension as a cardiovascular risk factor in end-stage renal failure. Zoccali, C., Mallamaci, F., Tripepi, G. Curr. Hypertens. Rep. (2002) [Pubmed]
  68. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Zoccali, C. Nephrol. Dial. Transplant. (2002) [Pubmed]
  69. Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. Zoccali, C., Mallamaci, F., Finocchiaro, P. J. Am. Soc. Nephrol. (2002) [Pubmed]
  70. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. Zoccali, C., Benedetto, F.A., Mallamaci, F., Tripepi, G., Giacone, G., Cataliotti, A., Seminara, G., Stancanelli, B., Malatino, L.S. J. Am. Soc. Nephrol. (2001) [Pubmed]
  71. The importance of large, high quality clinical databases in nephrology. Zoccali, C. J. Nephrol. (2001) [Pubmed]
 
WikiGenes - Universities